ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer
- 1 December 2018
- journal article
- editorial
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 17 (4) , 255-257
Abstract
No abstract availableFunding Information
- National Cancer Institute (R01 CA204173, UM1 CA186690, P30 CA047904)
This publication has 17 references indexed in Scilit:
- The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapyOncotarget, 2017
- ATM protein is deficient in over 40% of lung adenocarcinomasOncotarget, 2016
- Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) DatabaseJournal of Clinical Oncology, 2016
- ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cellsBlood, 2016
- Brd4 Shields Chromatin from ATM Kinase Signaling StormsScience Signaling, 2013
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset AnalysesJournal of Clinical Oncology, 2011
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutationsNature Structural & Molecular Biology, 2011
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATRNature Chemical Biology, 2011
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon CancerJournal of Clinical Oncology, 2011
- DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociationNature, 2003